Nanofiber compositions for a vaccine adjuvant, porous scaffold or porous membrane

Patent metadata

Field	Value
Publication number	US-12053521-B2
Application number	US-202016877185-A
Country	US
Kind code	B2
Filing date	May 18, 2020
Priority date	May 17, 2019
Publication date	Aug 6, 2024
Grant date	Aug 6, 2024

Abstract

An aspect is directed to a vaccine adjuvant including a nanofiber that comprises an oxide or a salt of one, two, three or more metals selected from the group of Al, Ca, Mg, Li, Na, K, La, Y, Si, Fe and Zn. Another aspect is directed to a porous scaffold or a porous membrane that comprises nanofibers comprising an oxide or a salt of one, two, three or more metals selected from the group of Al, Ca, Mg, Li, Na, K, La, Y, Si, Fe and Zn, where the porous scaffold or the porous membrane is configured for use in an environment where the nanofibers are exposed to a direct contact with extracellular body fluids.

First claim

The invention claimed is:

1. A nanofiber, comprising:
a compound comprising a primary metal, the primary metal comprising Al or Mg,
wherein the nanofiber is a non-agglomerated, individual nanofiber that exhibits a diameter in the range from around 1 nm to around 500 nm, a length in the range from around 250 nm to around 500 μm, an aspect ratio in the range from around 10 to around 100,000, a total pore volume in the range from around 0.01 cm 3 /g to around 3 cm 3 /g, and an average pore size in the range from around 0.5 nm to around 50 nm; and
an antigen and/or a vaccine adjuvant stored within one or more closed internal pores of the nanofiber.

2. The nanofiber of claim 1 , wherein the nanofiber aspect ratio ranges from around 100 to around 10,000, the nanofiber length ranges from around 1.5 μm to around 150 μm, the nanofiber average pore size ranges from around 0.5 nm to around 20 nm, and the total pore volume is in the range from around 0.05 cm 3 /g to around 1 cm 3 /g.

3. The nanofiber of claim 1 , wherein the nanofiber exhibits a positive surface charge in the range from around +2.00 mV to around +80.00 mV, as measured using Zeta-potential at a pH between about 7-8.

4. The nanofiber of claim 1 ,
wherein the nanofiber comprises a metal oxide and/or a metal salt.

5. The nanofiber of claim 4 , wherein the metal oxide and/or the metal salt is selected from: (i) the metal oxide, (ii) a metal hydroxide, (iii) a metal oxyhydroxide, (iv) a metal sulfate, (v) a metal carbide, (vi) a metal phosphate, (vii) a metal hydroxy phosphate, (viii) a metal hydroxy phosphate sulfate, (ix) a metal phosphate sulfate, (x) a metal hydroxy sulfate, (xi) a metal carbonate, (xii) a metal carbonate phosphate, and (xiii) a metal silicate.

6. The nanofiber of claim 1 , wherein Al constitutes between around 50 at. % to around 100 at. % of all the metals in the compound of the nanofiber.

7. The nanofiber of claim 1 , wherein Mg constitutes between around 50 at. % to around 100 at. % of all the metals in the compound of the nanofiber.

8. The nanofiber of claim 1 , wherein the compound comprises two or more metals with an atomic fraction of more than 0.01 at. % relative to all other metals in the compound.

9. The nanofiber of claim 1 , wherein the nanofiber is derived from a metal-organic nanofiber.

10. The nanofiber of claim 9 , wherein the metal-organic nanofiber is an alkoxide.

11. The nanofiber of claim 10 , wherein the alkoxide is a methoxide, an ethoxide, an iso-propoxide, or n-propoxide.

12. The nanofiber of claim 11 , wherein the metal-organic nanofiber is produced upon exposure of particles or chunks or bulk pieces of metals or Li-containing metal alloys to at least one alcohol.

13. The nanofiber of claim 1 , further comprising:
additional antigen and/or additional vaccine adjuvant stored within one or more open internal pores of the nanofiber.

14. The nanofiber of claim 1 , wherein the one or more closed internal pores of the nanofiber comprise the antigen.

15. The nanofiber of claim 1 , wherein the one or more closed internal pores of the nanofiber comprise the vaccine adjuvant.

16. The nanofiber of claim 1 , wherein the one or more closed internal pores of the nanofiber comprise the antigen and the vaccine adjuvant.

17. A nanofiber, comprising:
a compound comprising a primary metal, the primary metal comprising Al or Mg,
wherein the nanofiber is a non-agglomerated, individual nanofiber that exhibits a diameter in the range from around 1 nm to around 500 nm, a length in the range from around 250 nm to around 500 μm, an aspect ratio in the range from around 10 to around 100,000, a total pore volume in the range from around 0.01 cm 3 /g to around 3 cm 3 /g, and an average pore size in the range from around 0.5 nm to around 50 nm; and
an antigen and/or a vaccine adjuvant stored within one or more closed internal pores of the nanofiber,
wherein the compound further comprises:
a secondary metal selected from Ca, Li, Na, K, La, Y, Si, Fe and Zn.

18. The nanofiber of claim 17 , wherein Ca constitutes between around 50 at. % to around 100 at. % of all the metals in the compound of the nanofiber.

19. The nanofiber of claim 17 , wherein Zn constitutes between around 50 at. % to around 100 at. % of all the metals in the compound of the nanofiber.

20. A porous scaffold or a porous membrane, comprising:
nanofibers, each of the nanofibers being an instance of the nanofiber of claim 1 , wherein the porous scaffold or the porous membrane is configured for use in an environment where the nanofibers are exposed to a direct contact with extracellular body fluids.

21. The porous scaffold or porous membrane of claim 20 , wherein the porous scaffold or the porous membrane is configured to facilitate wound healing.

22. The porous scaffold or porous membrane of claim 21 , wherein the nanofibers comprise one or more antiseptic agents to combat bacteria or virus growth.

Assignees

• Sila Nanotechnologies Inc

Inventors

• Yushin Gleb
• Turcheniuk Kostiantyn
• Kulinski Kyle

Classifications

• A61L2400/12

  Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces · CPC title

• A61K2039/55505

  Inorganic adjuvants · CPC title

• A61K2039/55511

  Organic adjuvants · CPC title

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title

• A61K2039/55555

  Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers · CPC title